John C Sefter Jr., DO Orthopaedic Surgery - Orthopaedic Surgery of the Spine Medicare: Accepting Medicare Assignments Practice Location: 18 Deatrick Dr, Gettysburg, PA 17325 Phone: 717-339-2500 Fax: 717-339-2502 |
Eric D Nabors, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 18 Deatrick Dr, Gettysburg, PA 17325 Phone: 717-339-2500 Fax: 717-339-2502 |
Thomas A Little, MD Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 371 E. Water St, Ste #2, Gettysburg, PA 17325 Phone: 717-339-9029 |
Kyle J. Messick, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 18 Deatrick Drive, Gettysburg, PA 17325 Phone: 717-339-2500 Fax: 717-339-2502 |
Mr. Anthony Bruno, MD Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 18 Deatrick Dr, Gettysburg, PA 17325 Phone: 717-339-2500 Fax: 717-339-2500 |
Jesse Lee Sandlin, M.D. Orthopaedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 18 Deatrick Dr, Gettysburg, PA 17325 Phone: 717-339-2500 Fax: 717-339-2502 |
News Archive
Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.
It's Hepatitis Awareness Month. Understanding the different forms of hepatitis, who is at risk and how it can be prevented and treated can be confusing.
Fatigue and poor sleep quality, which affect many emergency medical services (EMS) workers, are linked to higher reported rates of injuries, medical errors and safety-compromising behaviors, according to a study by University of Pittsburgh researchers that is now available online in Prehospital Emergency Care and appearing in the January-March 2012 print edition.
Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.
A large nationwide longitudinal study found no evidence of an increased risk of cancer in children born near nuclear power plants in Switzerland.
› Verified 5 days ago